Key facts
- Made Scientific and Pluristyx have launched an integrated development and manufacturing partnership.
- The partnership focuses on advancing next-generation iPSC-derived cell therapies.
- Pluristyx's clinical-grade iPSC platform will be integrated into Made Scientific's CDMO services.
- The collaboration offers a single-source path for cell therapy developers.
Made Scientific and Pluristyx have announced a strategic partnership aimed at accelerating the development and manufacturing of next-generation induced pluripotent stem cell (iPSC)-derived cell therapies. The collaboration integrates Pluristyx's clinical-grade iPSC platform into Made Scientific's contract development and manufacturing organization (CDMO) services. This integration is designed to offer cell therapy developers a comprehensive, single-source solution, covering the entire process from cell line development through to commercial supply. The partnership is expected to streamline the path for bringing innovative cell therapies to market.